PDGFRB and neoplasm: Compounds 460–462 showed strong cytotoxicity against six HTCLs (HCT-116, HepG2, BGC-823, NCI-H1650, A2780, and MCF7) (IC50 = 1.3–12.5 μM) and exhibited selective significant inhibitory activity towards the human tumor-related protein kinases of FGFR3, IGF1R, PDGFRb, and TrKB (IC50 = 2.6–21.4 μM) [153].